Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | 0.17 | 0.07 |
| FCF Yield | -53.03% | -30.89% | -26.29% | -10.19% |
| EV / EBITDA | -2.40 | -1.52 | -1.62 | -4.55 |
| Quality | ||||
| ROIC | -9.69% | -11.42% | -15.69% | -13.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.36 | 0.59 | 0.39 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 538,136.13% | 538,136.13% | 538,136.13% |
| Free Cash Flow Growth | -119.75% | -19.10% | 3.94% | 20.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.48 | -0.08 | 0.09 |
| Interest Coverage | -88.33 | -51.02 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 12,466.07 | 15,479.57 | 9,594.57 | 11,517.32 |